Xenon Pharmaceuticals Inc (XENE) - Financial Analysis Review

Summary

Xenon Pharmaceuticals Inc (Xenon) is a biopharmaceutical company which discovers and develops a pipeline of differentiated therapeutics for orphan indications. The company's pipeline products include Glybera, XEN801, sodium channel inhibitor and TV-45070. Xenon through its core platform, Extreme Genetic, discovers various validated drug targets through the study of rare human diseases with extreme traits, including channelopathies, diseases caused by mutations in ion channels. Its platform comprises full complement of in-house capabilities for human genetics, small molecule drug discovery, and for pre-clinical and clinical development.

GlobalData's Xenon Pharmaceuticals Inc (XENE) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years.

Xenon Pharmaceuticals Inc Key Recent Developments:

Nov 03,2016: Xenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Sep 27,2016: Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors
Aug 03,2016: Xenon Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
May 10,2016: Xenon Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
Apr 04,2016: Xenon Names Dr. Raymond J. Winquist as Head, Translational Research


This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
- Business description - A detailed description of the company's operations and business divisions.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services.
- Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage,